Other: dose reduction to 2mg/l (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04222920 (ClinicalTrials.gov) | March 1, 2020 | 7/1/2020 | Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity | Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity: a Single Blind, Non-inferiority, Randomised Clinical Trial | Rheumatoid Arthritis | Other: Dose reduction to 2mg/L;Other: Dose reduction to 5mg/L;Drug: Adalimumab | Reade Rheumatology Research Institute | ZonMw: The Netherlands Organisation for Health Research and Development;Sint Maartenskliniek | Recruiting | 18 Years | N/A | All | 89 | Phase 4 | Netherlands |